<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00322764</url>
  </required_header>
  <id_info>
    <org_study_id>RG2417-01</org_study_id>
    <nct_id>NCT00322764</nct_id>
  </id_info>
  <brief_title>Phase II Study to Assess RG2417 in the Treatment of Bipolar I Depression</brief_title>
  <official_title>Dose-Escalating, Phase II Study to Assess the Safety and Tolerability of RG2417 in the Treatment of Bipolar I Depression</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Repligen Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Repligen Corporation</source>
  <brief_summary>
    <textblock>
      The primary purpose of this study is to determine the safety and efficacy of oral RG2417
      (Uridine) when administered to patients with Bipolar I depression twice daily for six weeks.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2006</start_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of MADRS and CGI BP C for RG2417 treatment in comparison to placebo</measure>
  </primary_outcome>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Bipolar Depression</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Uridine</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. DSM-IV-TR diagnosis of Bipolar I Depression

          2. 18 to 65 years of age, inclusive

          3. Depressive phase, as measured by MADRS greater than or equal to 20 at Screening and
             Day1

          4. Duration of current depressive episode of at least four weeks by Day 1

          5. Competent to give informed consent

        Exclusion Criteria:

          1. Manic/hypomanic/mixed episode as determined by the MINI at Screening and/or a Young
             Mania Rating Scale (YMRS) score of &gt; 12 at Screening and/or Day 1

          2. Dementia or any current Axis I diagnosis (excluding bipolar I) requiring
             pharmacological treatments

          3. A history of alcohol or substance dependence within six months of Day 1, or a history
             of alcohol or substance abuse within three months of Day 1

          4. Urine drug screen positive for amphetamines, cocaine metabolites, opiates and/or
             phencyclindine (PCP)

          5. An Axis II diagnosis that is likely to interfere with protocol compliance

          6. Initiation of or increase in psychotherapy within 4 weeks of Screening

          7. Psychotropic medication (excluding fluoxetine) within 24 hours of initiation of study
             drug on Day 1; fluoxetine within 2 weeks of initiation of study drug on Day 1

          8. Serious suicidal or homicidal risk as determined by the investigator and/or a score of
             &gt; 5 on the suicide item #10 of the MADRS at Screening and/or Day 1

          9. History of sensitivity to any of the ingredients in the study drug

         10. Clinically significant abnormality in any screening laboratory results

         11. Clinically significant organic disease, including cardiovascular, endocrine, hepatic,
             pulmonary, neurologic, or renal disease, or any other medical condition, serious
             intercurrent illness, or extenuating circumstances that, in the opinion of the
             investigator, would interfere with the performance or interpretability of, or put the
             patient at risk from, the study procedures

         12. Women who are pregnant, breastfeeding, or refuse to use adequate birth control

         13. Current seizure disorder

         14. Participation in an investigational drug study within twenty-eight days of Day 1

         15. Current psychotic episode

         16. Clozaril use and/or electroconvulsive therapy within six months of Day 1

         17. Failure of three or more adequate trials of standard therapies for depression during
             the current episode

         18. Current episode of depression is longer than one year
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>David Jacoby, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Repligen Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carman Research</name>
      <address>
        <city>Smyrna</city>
        <state>Georgia</state>
        <zip>30080</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Indiana University-Purdue University Indianapolis</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Marc Hertzman, MD, PC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20852</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical &amp; Behavioral Health Research, PC</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10023</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnati</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45267</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Austin</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Future Search Trials of Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center at San Antonio</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 4, 2006</study_first_submitted>
  <study_first_submitted_qc>May 4, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 8, 2006</study_first_posted>
  <last_update_submitted>November 8, 2007</last_update_submitted>
  <last_update_submitted_qc>November 8, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 9, 2007</last_update_posted>
  <keyword>manic depression</keyword>
  <keyword>bipolar disorder</keyword>
  <keyword>depression</keyword>
  <keyword>uridine</keyword>
  <keyword>RG2417</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

